Indivior Pharmaceuticals stock after recent performance

Indivior Pharmaceuticals (INDV) has drawn fresh attention after recent share performance, with the stock closing at $36.99 and showing mixed short term returns alongside longer period total returns that differ sharply by timeframe.

At the current share price of $36.99, Indivior Pharmaceuticals shows strong longer term momentum, with a 30 day share price return of 13.12% and a 1 year total shareholder return of 223.34%, even though the 7 day share price return declined 3.37%.

If you are looking beyond a single stock, this may be a good moment to broaden your watchlist with 29 healthcare AI stocks

With revenue of $1.29b, net income of $252m and a $4.46b market cap, plus a value score of 4 and an implied discount to a $51.50 target, is there still an opportunity in this stock, or is the market already fully reflecting its prospects?

Most Popular Narrative: 2.3% Undervalued

Indivior Pharmaceuticals' most followed narrative points to a fair value of $37.86, which sits slightly above the last close at $36.99 and frames a modest discount.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Want to see what kind of revenue trajectory, margin profile and earnings power this narrative is baking in, and how that ties back to the $37.86 fair value? The full storyline lays out a detailed link between projected profitability, valuation multiples and the discount rate that underpins this pricing view.

Result: Fair Value of $37.86 (UNDERVALUED)

However, there is still a risk that tighter cost controls and the Indivior Action Agenda could lift margins and earnings beyond what this modest undervaluation implies.

Next Steps

The mix of optimism and concern around Indivior Pharmaceuticals is clear, so do not leave your view half formed. Take a closer look at the balance of 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop here, you might miss stocks that better match your goals, so keep building your watchlist with a few focused ideas.

• Target reliable income by checking out 12 dividend fortresses that aim to combine stability with meaningful yields.
• Hunt for quality at a reasonable price through screener containing 21 high quality undiscovered gems before they appear on everyone else's radar.
• Prioritise resilience by reviewing 66 resilient stocks with low risk scores that score well on financial strength and business stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.